Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

Merck is playing catch-up in the category with Bayer and Ionis, as their antisense-based Factor XI inhibitor fesomersen has already shown efficacy against clotting, with no increase in bleeding ...

Spoiler alert: Three years into separate six-year deals with Bayer and Merck, demand for the contraceptives is even higher than originally forecast. From 4.7 million in 2012, the annual run rate ...

Merck has development and commercialization agreements with AstraZeneca, Daiichi Sankyo, and LaNova. It also has collaboration agreements with Bayer, Eisai, Moderna, and Ridgeback Biotherapeutics.

Recursion has ongoing collaboration agreements with pharma giants like Roche, Bayer, Merck MRK and Sanofi to develop candidates for several oncology indications with differentiated mechanisms of ...

(3) Alliance Revenue represents royalties. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and ...

L.L. has acted as a consultant for Merck, Novartis, and Bayer, and has received grants from Pfizer, Bayer, Merck, and Novartis. D.C.B. has served on the steering committee as a consultant for Merck.

(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product ...